{"schema_version":"1.0","hypothesis_id":35466,"triple":{"drug":"ocrelizumab","drug_canonical":"ocrelizumab","mediator":"CD20","mediator_canonical":"cd20","outcome":"CDAI","outcome_canonical":"cdai"},"domain":{"domain":"cross_domain","source":"multiple_sclerosis","target":"rheumatoid_arthritis"},"provenance_completeness":"partial_backfill","completeness_notes":"Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.","source_papers":[{"doi":"10.3389/fnins.2025.1685209","pmid":"41357832","year":2025,"roles":["drug_mediator"],"title":"Late-onset severe neutropenia in patients with relapsing remitting multiple sclerosis treated with ocrelizumab: case report and literature review","journal":"Front Neurosci","work_id":209144,"publication_date":"2025-11-20"},{"doi":"10.1038/s41598-024-75745-y","pmid":"39438591","year":2024,"roles":["drug_mediator"],"title":"Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial","journal":"Sci Rep","work_id":207629,"publication_date":"2024-10-22"},{"doi":"10.1136/bmjno-2024-000672","pmid":"38912173","year":2024,"roles":["drug_mediator"],"title":"Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study","journal":"BMJ Neurol Open","work_id":207289,"publication_date":"2024-06-01"},{"doi":"10.1016/j.msard.2024.105570","pmid":"38604001","year":2024,"roles":["drug_mediator"],"title":"Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers","journal":"Mult Scler Relat Disord","work_id":198063,"publication_date":"2024-03-30"},{"doi":"10.1016/j.msard.2023.105147","pmid":"38043368","year":2023,"roles":["drug_mediator"],"title":"Neutropaenia complications from Ocrelizumab and Rituximab treatment","journal":"Mult Scler Relat Disord","work_id":201666,"publication_date":"2023-11-21"},{"doi":"10.1007/s13311-023-01415-y","pmid":"37610702","year":2023,"roles":["drug_mediator"],"title":"Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)","journal":"Neurotherapeutics","work_id":197723,"publication_date":"2023-08-23"},{"doi":"10.4103/aian.aian_526_22","pmid":"36911456","year":2022,"roles":["drug_mediator"],"title":"Successful Rapid Desensitization of a Pediatric Multiple Sclerosis Patient with Anaphylaxis to Ocrelizumab","journal":"Ann Indian Acad Neurol","work_id":213656,"publication_date":"2022-11-01"},{"doi":"10.3389/fimmu.2022.840238","pmid":"35222433","year":2022,"roles":["drug_mediator"],"title":"Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe","journal":"Front Immunol","work_id":210677,"publication_date":"2022-02-09"},{"doi":"10.1016/j.nrl.2021.01.010","pmid":"33726971","year":2021,"roles":["drug_mediator"],"title":"Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab","journal":null,"work_id":207051,"publication_date":"2021-03-13"},{"doi":"10.1177/11795735211037785","pmid":"34497472","year":2021,"roles":["drug_mediator"],"title":"Breast Carcinoma After Ocrelizumab Therapy in Multiple Sclerosis Patients: A Case Series and Literature Review","journal":"J Cent Nerv Syst Dis","work_id":205227,"publication_date":"2021-01-01"},{"doi":"10.1016/j.msard.2020.102492","pmid":"33039944","year":2020,"roles":["drug_mediator"],"title":"Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis","journal":"Mult Scler Relat Disord","work_id":199954,"publication_date":"2020-09-24"},{"doi":"10.1038/s41598-019-44895-9","pmid":"31186464","year":2019,"roles":["mediator_outcome"],"title":"General synovitis score and immunologic synovitis score reflect clinical disease activity in patients with advanced stage rheumatoid arthritis","journal":"Sci Rep","work_id":290504,"publication_date":"2019-06-11"},{"doi":"10.1212/wnl.0000000000006924","pmid":"30635476","year":2019,"roles":["drug_mediator"],"title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","journal":"Neurology","work_id":198546,"publication_date":"2019-01-12"},{"doi":"10.33588/rn.6612.2018132","pmid":"29897610","year":2018,"roles":["drug_mediator"],"title":"Ocrelizumab: eficacia y seguridad en la esclerosis múltiple","journal":"Rev Neurol","work_id":203976,"publication_date":"2018-01-01"}],"source_paper_count":14,"extracted_claims":[{"side":"drug_mediator","object":"CD20","context":"recombinant humanized monoclonal antibody targeting CD20-expressing B cells","subject":"Ocrelizumab","work_id":197723,"claim_id":143650,"polarity":"positive","predicate":"binds_to","confidence":1.0,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"not specified","subject":"ocrelizumab","work_id":198063,"claim_id":144243,"polarity":"positive","predicate":"binds_to","confidence":0.9,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"for multiple sclerosis treatment","subject":"ocrelizumab","work_id":198546,"claim_id":145144,"polarity":"positive","predicate":"binds_to","confidence":0.95,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"in patients with relapsing-remitting multiple sclerosis","subject":"ocrelizumab","work_id":199954,"claim_id":147406,"polarity":"positive","predicate":"binds_to","confidence":0.9,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"in multiple sclerosis treatment","subject":"Ocrelizumab","work_id":201666,"claim_id":150122,"polarity":"positive","predicate":"binds_to","confidence":0.9,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"in multiple sclerosis","subject":"Ocrelizumab","work_id":203976,"claim_id":153164,"polarity":"positive","predicate":"binds_to","confidence":0.9,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"as a humanized CD20 monoclonal antibody","subject":"ocrelizumab","work_id":205227,"claim_id":154850,"polarity":"neutral","predicate":"binds_to","confidence":0.95,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"general","subject":"ocrelizumab","work_id":207051,"claim_id":157219,"polarity":"positive","predicate":"binds_to","confidence":1.0,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"in vitro","subject":"ocrelizumab","work_id":207289,"claim_id":157545,"polarity":"positive","predicate":"binds_to","confidence":0.9,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"in relapsing multiple sclerosis","subject":"ocrelizumab","work_id":207629,"claim_id":158001,"polarity":"positive","predicate":"binds_to","confidence":0.95,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"as anti-CD20 therapy","subject":"ocrelizumab","work_id":209144,"claim_id":159654,"polarity":"positive","predicate":"binds_to","confidence":0.95,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"in multiple sclerosis treatment","subject":"Ocrelizumab","work_id":210677,"claim_id":161398,"polarity":"positive","predicate":"binds_to","confidence":0.9,"extraction_run_id":25},{"side":"drug_mediator","object":"CD20","context":"humanized monoclonal antibody targeting CD20-positive B-cells","subject":"ocrelizumab","work_id":213656,"claim_id":163848,"polarity":"positive","predicate":"binds_to","confidence":0.95,"extraction_run_id":25},{"side":"mediator_outcome","object":"CDAI","context":"in synovial tissue of patients with advanced stage rheumatoid arthritis","subject":"CD20","work_id":290504,"claim_id":222259,"polarity":"positive","predicate":"correlates_with","confidence":0.8,"extraction_run_id":29}],"extracted_claim_count":14,"extraction":{"model":"deepseek-v4-flash","model_source":"configured","prompt_version":"v1_2026_05_07","run_ids":[25,29]},"bridge":{"a_to_b_predicate":"binds_to","b_to_c_predicate":"correlates_with","a_to_b_evidence_count":13,"b_to_c_evidence_count":1,"edge_support_log_ab":2.6390573296152584,"edge_support_log_bc":0.6931471805599453,"novelty_factor":1.0,"direct_a_to_c_count":0},"embedding":{"model":"bge-m3","dim":1024,"max_length":8192,"similarity_scores":{}},"scoring":{"method":"swanson_abc_log_evidence_with_novelty_penalty","formula":"score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)","score_raw":0.3332204510175204,"score":0.3332204510175204,"quality_tier":"high","quality_reason":null},"pipeline_run":{"id":4,"run_uuid":"eb8b7730-d92e-4cd5-95dd-95f6c5d62cc2","command":"scripts/backfill_provenance_v2.py:v2_2026_05_12","status":"completed","git_commit":"9996ffaa56e9b7cd5f677bd8203624c2c18aa000","host":"MacBook-Pro-Daniel96.local","started_at":"2026-05-12T21:35:53.363326+00:00","ended_at":"2026-05-12T21:43:41.903387+00:00","notes":"Retroactive provenance backfill on 2026-05-13 for snapshot v2_2026_05_12. Synthetic pipeline_runs row — original generation run records are lost (pre-date provenance schema). All recoverable fields populated from current DB state (claims, works, repurposing_hypotheses); pipeline_run record is synthetic, hence completeness='partial_backfill'.\nBackfilled 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.","domains":["als","alzheimer","depression","epilepsy","glioblastoma","inflammatory_bowel_disease","multiple_sclerosis","pancreatic_cancer","rheumatoid_arthritis","type_2_diabetes"]},"generated_at":"2026-05-12T21:43:40.945575+00:00"}